nafronyl has been researched along with Bronchitis in 1 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, AJ | 1 |
| Osman, J | 1 |
| Skinner, C | 1 |
1 trial available for nafronyl and Bronchitis
| Article | Year |
|---|---|
Effects of naftidrofuryl on breathlessness and exercise tolerance in chronic bronchitis.
Topics: Aged; Bronchitis; Chronic Disease; Female; Furans; Humans; Lung; Male; Middle Aged; Nafronyl; Physic | 1982 |